MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria Inc. Receives Multi-Year $3.47 Million U.S. NIH Phase I and Phase II Small Business Innovation Research Grants to Enhance Development of its Malaria Vaccine
Sanaria Inc., a Rockville, Maryland privately held company, announced the receipt of two multi-year Small Business Innovation Research (SBIR) Grants from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. The grants will enhance the development of its whole parasite Malaria Vaccine. The Phase II grant is to establish multiple strains of the parasite that can be used to assess the effectiveness of Sanaria's Malaria Vaccine.
Bush recognizes social entrepreneurship
Like many such events, the recent White House Summit on malaria, which featured a speech and new grant announcements by Melinda Gates, was carefully choreographed with few surprises. But there was one. President Bush began the closing keynote address by saying, “I want to thank those members of my Cabinet who are here, the ambassadors, the members of Congress, and I want to thank the social entrepreneurs who are with us today.” Bush then cited the Bill & Melinda Gates Foundation as “a fantastic example of social entrepreneurship, using business acumen to address social problems.” Read more in the original Seattle PI article, with its discussion of Sanaria’s approach to malaria vaccines and its business model.
$29.3M Gates grant boosts Sanaria
With the grant by the Bill and Melinda Gates Foundation announced Thursday, plus a new partnership with the Malaria Vaccine Initiative, Sanaria has reached $45 million in funding for developing a malaria vaccine.
Mosquito ‘factories’ to fight malaria
It's going to be fiddly work, but the saliva glands of mosquitoes are to be used as mini factories for churning out a novel vaccine against malaria. The vaccine is based on the whole parasite, rather than individual proteins, and may therefore work better than other vaccines in development because the body can mount a multi-pronged attack against it.
PATH Malaria Vaccine Initiative Announces New Partnership To Accelerate Development of Novel Malaria Vaccine Candidate MVI and Sanaria Inc. to Conduct Initial Safety and Test-of-Concept Trial
In a move that promises to expand the types of malaria vaccine candidates in clinical development, the PATH Malaria Vaccine Initiative (MVI) today announced a new partnership with Sanaria Inc., a Maryland company, to accelerate development of a unique malaria vaccine candidate.
A conversation with Stephen Hoffman
Scientist survives several near misses — including a crash-landing — before turning his efforts toward fighting malaria Off on his own in South America, he gets typhoid. In California, he is infected with malaria. On his way to a research site in Africa, the plane carrying him crash-lands. Is Stephen Hoffman, the leader of malaria-vaccine developer Sanaria, scared by his past skirmishes with death? Sometimes. Read the full story in the latest Washington Business Journal.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.